[Clinical research on the hypolipidemic action of a probucol preparation].
Probucol is a drug with hypolipidemic effect from the group of diphenols. The preparation has been administered to 33 patients with hyperlipoproteinemia--15 with type IIA, 17--with IIB and 1--with type III, in a dose of 750 mg for 28 days. The following serum indices were studied: total cholesterol (TCh), cholesterol in lipoproteins with high density (Ch-HDL), triglycerides (Tg), percentage of free cholesterol FCh) and ester cholesterol (ECh) in HDL and lipid-acid composition of ECh in HDL and lipoproteins with low density (LDL). The preparation has a good tolerance. By the end of the treatment, TCh was significantly reduced in the patients with type IIA--with 28.4% (p less than 0.001) and in IIB--with 23.3% (p less than 0.001). Ch-HDL was reduced with 19% on the average in type II ChLD (p less than 0.001). An essential reduction of serum Tg was established--with 32.2%. Significant reduction of lipid acids in the composition of ECh and HDL was established in type IIA ChLD.